Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse ...
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse ...
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab ...
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of ...
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of ...
1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.